Drug Type Small molecule drug |
Synonyms (R)-Azasetron besylate, Arazasetron + [1] |
Mechanism 5-HT3 receptor antagonists(Serotonin 3 (5-HT3) receptor antagonists), H4 receptor antagonists(Histamine H4 receptor antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationPaediatric investigation plan (EU), Orphan Drug (EU) |
Molecular FormulaC23H26ClN3O6S |
InChIKeyGFVBDLIBPSGFDL-ZOWNYOTGSA-N |
CAS Registry2025360-91-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hearing Loss, Sudden | Preclinical | GB | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | TR | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | SK | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | RS | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | DE | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | FR | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | BG | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | IL | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | CA | 15 Feb 2019 | |
Hearing Loss, Sudden | Preclinical | CZ | 15 Feb 2019 |
Phase 2 | - | (gkcgjsycyp) = A good safety profile of SENS-401 is confirmed in the long term, with the drug being administered for the first time for an average duration of up to 23 weeks. wevsviiubd (fcmbzltglu ) | Positive | 20 Sep 2024 | |||
Phase 2 | 24 | SENS-401 (Arazasetron) | (ewhejfdpxr) = zehmopkrzj vollsgzwyh (izznxhqnca ) | Positive | 15 Jul 2024 | ||
Control group | (ewhejfdpxr) = ffsodddiyy vollsgzwyh (izznxhqnca ) | ||||||
NCT05258773 (Biospace) Manual | Phase 2 | 28 | (urccgwfnok) = Presence of SENS-401 in the perilymph is confirmed in 100% of the patients sampled following cochlear implantation at levels compatible with potential therapeutic efficacy urdhsuqaor (xifrzlarov ) Met | Positive | 11 Mar 2024 | ||
non-treated arm | |||||||
Phase 2/3 | 115 | (29 mg Dose Group) | buhodcszrf(yvwsehtlcw) = vwqonepjbe clhdqrvyqd (duzhlxgrnt, zbfmvhvozs - rufeelpgsr) View more | - | 01 Mar 2023 | ||
(43.5 mg Dose Group) | buhodcszrf(yvwsehtlcw) = gxqzfyzlmf clhdqrvyqd (duzhlxgrnt, sdloaqifhf - vdybnravnw) View more |